Clovis Oncology Profile

USD 0.76  1.62%

Clovis Oncology exotic insider transaction detected

Clovis Oncology insider trading alert for general transaction of common stock by Patrick Mahaffy, President and CEO, on July 16, 2018. This event was filed by Clovis Oncology Inc with SEC on 2011-11-15. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Clovis Oncology Summary

Clovis Oncology (CLVS) is traded on NASDAQ in USA. It is located in 5500 Flatiron Parkway and employs 360 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.47 B. Clovis Oncology conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 52.55 M outstanding shares of which 7.8 M shares are currently shorted by private and institutional investors with about 8.01 trading days to cover. Clovis Oncology currently holds about 463.81 M in cash with (281.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.83.
Check Clovis Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 47.8HorizonTargetOdds Above 47.8
71.07%30 days 47.80 28.63%
Based on normal probability distribution, the odds of Clovis Oncology to move above current price in 30 days from now is about 28.63% (This Clovis Oncology probability density function shows the probability of Clovis Oncology Stock to fall within a particular range of prices over 30 days) .

Top Holders

Clovis Oncology Risk Profiles

Key Fundamentals

Clovis Oncology Against Markets

Current Ratings

Clovis Oncology 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Clovis Oncology are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 360 people. more
NameClovis Oncology
President CEO, DirectorPatrick MahaffyView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address5500 Flatiron Parkway
IndustryPharmaceutical Products
Phone303 625 5000
CurrencyUSD - US Dollar

Clovis Oncology Corporate Directors

James Blair Independent Director
Thorlef Spickschen Independent Director, Ph.D
Brian Atwood Independent Director, MBA
Check also Trending Equities. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.